MEDIFAST INC
For the period ended Feb 20, 2024. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Feb 20, 2024 · Filed Feb 20, 2024
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Outlook
Outlook
The company expects first quarter 2024 revenue to be in the range of $155 million to $175 million and first quarter 2024 diluted EPS to be in the range of $0.25 to $0.95. The EPS range excludes the costs related to the initiation of the LifeMD collaboration and any gains or losses from changes in the market price of the company’s LifeMD common stock investment.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.